






Tobira Therapeutics, Inc. - Product Pipeline Review - 2014























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
Tobira Therapeutics, Inc. - Product Pipeline Review - 2014









 


  Tobira Therapeutics, Inc. - Product Pipeline Review - 2014


WGR12400
24 
                  December, 2014 
Global
25 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





Tobira Therapeutics, Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Tobira Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Tobira Therapeutics, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Tobira Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Tobira Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Tobira Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the Tobira Therapeutics, Inc.’s pipeline productsReasons to buy- Evaluate Tobira Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Tobira Therapeutics, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Tobira Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Tobira Therapeutics, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tobira Therapeutics, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Tobira Therapeutics, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Tobira Therapeutics, Inc. Snapshot 4Tobira Therapeutics, Inc. Overview 4Key Information 4Key Facts 4Tobira Therapeutics, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Tobira Therapeutics, Inc. - Pipeline Review 7Pipeline Products by Stage of Development 7Pipeline Products - Monotherapy 8Pipeline Products - Combination Treatment Modalities 9Tobira Therapeutics, Inc. - Pipeline Products Glance 10Tobira Therapeutics, Inc. - Clinical Stage Pipeline Products 10Phase II Products/Combination Treatment Modalities 10Tobira Therapeutics, Inc. - Early Stage Pipeline Products 11Preclinical Products/Combination Treatment Modalities 11Tobira Therapeutics, Inc. - Drug Profiles 12(cenicriviroc + lamivudine + efavirenz) 12Product Description 12Mechanism of Action 12R&D Progress 12(cenicriviroc + lamivudine) 13Product Description 13Mechanism of Action 13R&D Progress 13cenicriviroc 14Product Description 14Mechanism of Action 14R&D Progress 14Tobira Therapeutics, Inc. - Pipeline Analysis 16Tobira Therapeutics, Inc. - Pipeline Products by Target 16Tobira Therapeutics, Inc. - Pipeline Products by Route of Administration 17Tobira Therapeutics, Inc. - Pipeline Products by Molecule Type 18Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action 19Tobira Therapeutics, Inc. - Recent Pipeline Updates 20Tobira Therapeutics, Inc. - Dormant Projects 22Tobira Therapeutics, Inc. - Locations And Subsidiaries 23Head Office 23Other Locations & Subsidiaries 23Appendix 24Methodology 24Coverage 24Secondary Research 24Primary Research 24Expert Panel Validation 24Contact Us 25Disclaimer 25List of TablesTobira Therapeutics, Inc., Key Information 4Tobira Therapeutics, Inc., Key Facts 4Tobira Therapeutics, Inc. - Pipeline by Indication, 2014 6Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2014 7Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8Tobira Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 9Tobira Therapeutics, Inc. - Phase II, 2014 10Tobira Therapeutics, Inc. - Preclinical, 2014 11Tobira Therapeutics, Inc. - Pipeline by Target, 2014 16Tobira Therapeutics, Inc. - Pipeline by Route of Administration, 2014 17Tobira Therapeutics, Inc. - Pipeline by Molecule Type, 2014 18Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 19Tobira Therapeutics, Inc. - Recent Pipeline Updates, 2014 20Tobira Therapeutics, Inc. - Dormant Developmental Projects,2014 22Tobira Therapeutics, Inc., Other Locations 23List of FiguresTobira Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 6Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2014 7Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8Tobira Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 16Tobira Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 17Tobira Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 18Tobira Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 19







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,154.10
   

 
  Site PDF 
  
 
  2,308.20
  

 
  Enterprise PDF 
  
 
  3,462.30
  





  1-user PDF
  
 
    1,285.80
   

 
  Site PDF 
  
 
  2,571.60
  

 
  Enterprise PDF 
  
 
  3,857.40
  





  1-user PDF
  
 
    166,692.00
   

 
  Site PDF 
  
 
  333,384.00
  

 
  Enterprise PDF 
  
 
  500,076.00
  





  1-user PDF
  
 
    96,718.65
   

 
  Site PDF 
  
 
  193,437.30
  

 
  Enterprise PDF 
  
 
  290,155.95
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 






































Tobira Therapeutics, Inc. - Product Pipeline Review - 2015































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map











Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies > Pharma Info









Market Research Report
Tobira Therapeutics, Inc. - Product Pipeline Review - 2015



Published by
Global Markets Direct
Product code
253686


Published
June 24, 2015
Content info
33 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























Tobira Therapeutics, Inc. - Product Pipeline Review - 2015



Published: June 24, 2015
Content info: 33 Pages














Description

Summary
Global Markets Direct's, 'Tobira Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Tobira Therapeutics, Inc.'s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Tobira Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope

 The report provides brief overview of Tobira Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
 The report reviews current pipeline of Tobira Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
 The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 Special feature on out-licensed and partnered product portfolio
 The report summarizes all the dormant and discontinued pipeline projects
 Latest company statement
 Latest news and deals relating to the Tobira Therapeutics, Inc.'s pipeline products

Reasons to buy

 Evaluate Tobira Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
 Assess the growth potential of Tobira Therapeutics, Inc. in its therapy areas of focus
 Identify new drug targets and therapeutic classes in the Tobira Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 Develop strategic initiatives by understanding the focus areas of Tobira Therapeutics, Inc. and exploit collaboration and partnership opportunities
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tobira Therapeutics, Inc.
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Explore the dormant and discontinued projects of Tobira Therapeutics, Inc. and identify potential opportunities in those areas
 Avoid Intellectual Property Rights related issues




Table of Contents
Product Code: GMDHC07163CDBTable of Contents

Table of Contents 

List of Tables 
List of Figures 

Tobira Therapeutics, Inc. Snapshot 

Tobira Therapeutics, Inc. Overview 
Key Information 
Key Facts 

Tobira Therapeutics, Inc. - Research and Development Overview 

Key Therapeutic Areas 

Tobira Therapeutics, Inc. - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 
Pipeline Products - Combination Treatment Modalities 

Tobira Therapeutics, Inc. - Pipeline Products Glance 

Tobira Therapeutics, Inc. - Clinical Stage Pipeline Products 

Phase II Products/Combination Treatment Modalities 
Phase I Products/Combination Treatment Modalities 

Tobira Therapeutics, Inc. - Early Stage Pipeline Products 

Preclinical Products/Combination Treatment Modalities 


Tobira Therapeutics, Inc. - Drug Profiles 

(cenicriviroc mesylate + lamivudine + efavirenz) 

Product Description 
Mechanism of Action 
R&D Progress

(cenicriviroc mesylate + lamivudine) 

Product Description 
Mechanism of Action 
R&D Progress

cenicriviroc mesylate 

Product Description 
Mechanism of Action 
R&D Progress

REG-2 

Product Description 
Mechanism of Action 
R&D Progress

REG-3 

Product Description 
Mechanism of Action 
R&D Progress


Tobira Therapeutics, Inc. - Pipeline Analysis 

Tobira Therapeutics, Inc. - Pipeline Products by Target 
Tobira Therapeutics, Inc. - Pipeline Products by Route of Administration 
Tobira Therapeutics, Inc. - Pipeline Products by Molecule Type 
Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action 

Tobira Therapeutics, Inc. - Recent Pipeline Updates 
Tobira Therapeutics, Inc. - Dormant Projects 
Tobira Therapeutics, Inc. - Discontinued Pipeline Products 

Discontinued Pipeline Product Profiles 

REG-1 


Tobira Therapeutics, Inc. - Locations And Subsidiaries 

Head Office 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

Tobira Therapeutics, Inc., Key Information 
Tobira Therapeutics, Inc., Key Facts 
Tobira Therapeutics, Inc. - Pipeline by Indication, 2015 
Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015 
Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 
Tobira Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015 
Tobira Therapeutics, Inc. - Phase II, 2015 
Tobira Therapeutics, Inc. - Phase I, 2015 
Tobira Therapeutics, Inc. - Preclinical, 2015 
Tobira Therapeutics, Inc. - Pipeline by Target, 2015 
Tobira Therapeutics, Inc. - Pipeline by Route of Administration, 2015 
Tobira Therapeutics, Inc. - Pipeline by Molecule Type, 2015 
Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 
Tobira Therapeutics, Inc. - Recent Pipeline Updates, 2015 
Tobira Therapeutics, Inc. - Dormant Developmental Projects,2015 
Tobira Therapeutics, Inc. - Discontinued Pipeline Products, 2015 

List of Figures

Tobira Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 
Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015 
Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 
Tobira Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 
Tobira Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 
Tobira Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 
Tobira Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports
















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.





  TBRA Stock Quote - Tobira Therapeutics Inc - Bloomberg Markets                     



     Error: Could not add to watchlist. X   + Watchlist  Tobira Therapeutics Inc   TBRA:US      Acquired   TBRA:US was acquired by AGN:US   USD             Volume   0                  


                Before it's here, it's on the Bloomberg Terminal.
            

                Learn More
            

         Volume   0    Current P/E Ratio (TTM)   -    Earnings per Share (USD) (TTM)   -2.46    Market Cap (USD)   -    Shares Outstanding  (m)   18.821    Price/Sales (TTM)   -    Dividend Indicated Gross Yield   -        Sector Health Care   % Price Change -0.06%     Industry Pharmaceuticals, Biotechnology & Life Sciences   % Price Change +0.10%                    Related Videos  There are currently no related videos for this ticker. Please check back later.    Company News Press Releases    9/21/2016   Stocks Hold Higher as Fed's Yellen Says Economy Picking Up  - The Street     9/21/2016   Stocks Add to Gains After Fed Leaves Rates Unchanged  - The Street     9/21/2016   Stocks Add to Gains After Fed Leaves Rates Unchanged  - The Street     9/21/2016   Stocks Yo Slightly in Countdown to Fed Announcement  - The Street     9/21/2016   Stocks Trade Higher in Countdown to Fed Announcement  - The Street    There are currently no news stories for this ticker. Please check back later.    There are currently no press releases for this ticker. Please check back later.      Profile   Tobira Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on developing and commercializing innovative therapeutics to treat liver diseases, human immunodeficiency virus, and fibrosis and inflammation. Tobira Therapeutics conducts business in the United States.    Address  701 Gateway BlvdSuite 300South San Francisco, CA 94080United States   Phone  1-650-741-6625   Website   www.tobiratx.com     Executives Board Members    Laurent Fischer  Chief Executive Officer    Helen Jenkins  Chief Operating Officer    Eric Lefebvre  Chief Medical Officer     Show More         




















Tobira Therapeutics, Inc. - Product Pipeline Review - 2015

















































































ABOUT US
BLOG
CONTACT US
FAQ























USD
EUR
GBP



USD 
▼

USD
EUR
GBP






€
EUR
$
USD
£
GBP







+353-1-416-8900REST OF WORLD



1-800-526-8630U.S. (TOLL FREE)








 




Advanced








Price From: 
€1335EUR$1,500USD£1,198GBP 
View Pricing




You are here:


Home
>






Categories
>






Company Reports











 
SELECT A FORMAT








€1335EUR$1,500USD£1,198GBP



                                                        Single User
                                                         Electronic (PDF)






                                                                            
                                                                            This is a single user license, allowing one specific user access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                










€2670EUR$3,000USD£2,395GBP



                                                        Site License
                                                         Electronic (PDF)






                                                                            
                                                                            This is a site license, allowing all users within a given geographical location of your organisation access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                










€4005EUR$4,500USD£3,593GBP



                                                        Enterprisewide
                                                         Electronic (PDF)






                                                                            
                                                                            This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                







  ADD TO BASKET




                                                                        order by fax
                                        

                                            need a quote ?
                                        



 

OUR CLIENTS












HAVE A QUESTION?
EMAIL US
VIEW FAQs



RECENTLY VIEWED PRODUCTS











Partner of Research and MarketsVACCINATING 40,000 CHILDREN IN 2017





WHY CHOOSE RESEARCH AND MARKETS?



WORLD'S LARGEST SELECTION




TRUSTED BY THE BEST




CUSTOMER FOCUSED




SAFE & SECURE







As far as I'm concerned, the ordering process was smooth, the
communication abundantly clear, and the

                         service prompt. Thank you!
                        
                    



                            READ MORE
                        


Mr Mansoor Siddiqi
Co Founder
Liquefy Innovations















Tobira Therapeutics, Inc. - Product Pipeline Review - 2015



ID: 3334725
Company Profile
June 2015
33 pages

Global Markets Direct                            











DESCRIPTION


TABLE OF CONTENTS


SAMPLES


FORMATS







1 of 4











                            LOGIN TO ACCESS EXECUTIVE SUMMARY
                        



                            PRINTER FRIENDLY
                        



                            PRINTABLE PDF BROCHURE
                        

SEND TO A FRIEND






                                                                                    Tobira Therapeutics, Inc. - Product Pipeline Review - 2015SummaryThis, ‘Tobira Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Tobira Therapeutics, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Tobira Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Tobira Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Tobira Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones- Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement- Latest news and deals relating to the Tobira Therapeutics, Inc.’s pipeline productsReasons to buy- Evaluate Tobira Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Tobira Therapeutics, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Tobira Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Tobira Therapeutics, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tobira Therapeutics, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Tobira Therapeutics, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues
                                                                                

 SHOW LESS
                                                                                

 READ MORE
                                                                                



Note: Product cover images may vary from those shown




2 of 4







                            LOGIN TO ACCESS EXECUTIVE SUMMARY
                        



                            PRINTER FRIENDLY
                        



                            PRINTABLE PDF BROCHURE
                        

SEND TO A FRIEND






                                                                    List of TablesList of FiguresTobira Therapeutics, Inc. SnapshotTobira Therapeutics, Inc. OverviewKey InformationKey FactsTobira Therapeutics, Inc. - Research and Development OverviewKey Therapeutic AreasTobira Therapeutics, Inc. - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyPipeline Products - Combination Treatment ModalitiesTobira Therapeutics, Inc. - Pipeline Products GlanceTobira Therapeutics, Inc. - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesPhase I Products/Combination Treatment ModalitiesTobira Therapeutics, Inc. - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesTobira Therapeutics, Inc. - Drug Profiles(cenicriviroc mesylate + lamivudine + efavirenz)Product DescriptionMechanism of ActionR&D Progress(cenicriviroc mesylate + lamivudine)Product DescriptionMechanism of ActionR&D Progresscenicriviroc mesylateProduct DescriptionMechanism of ActionR&D ProgressREG-2Product DescriptionMechanism of ActionR&D ProgressREG-3Product DescriptionMechanism of ActionR&D ProgressTobira Therapeutics, Inc. - Pipeline AnalysisTobira Therapeutics, Inc. - Pipeline Products by TargetTobira Therapeutics, Inc. - Pipeline Products by Route of AdministrationTobira Therapeutics, Inc. - Pipeline Products by Molecule TypeTobira Therapeutics, Inc. - Pipeline Products by Mechanism of ActionTobira Therapeutics, Inc. - Recent Pipeline UpdatesTobira Therapeutics, Inc. - Dormant ProjectsTobira Therapeutics, Inc. - Discontinued Pipeline ProductsDiscontinued Pipeline Product ProfilesREG-1Tobira Therapeutics, Inc. - Locations And SubsidiariesHead OfficeAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer   List of TablesTobira Therapeutics, Inc., Key InformationTobira Therapeutics, Inc., Key FactsTobira Therapeutics, Inc. - Pipeline by Indication, 2015Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015Tobira Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015Tobira Therapeutics, Inc. - Phase II, 2015Tobira Therapeutics, Inc. - Phase I, 2015Tobira Therapeutics, Inc. - Preclinical, 2015Tobira Therapeutics, Inc. - Pipeline by Target, 2015Tobira Therapeutics, Inc. - Pipeline by Route of Administration, 2015Tobira Therapeutics, Inc. - Pipeline by Molecule Type, 2015Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015Tobira Therapeutics, Inc. - Recent Pipeline Updates, 2015Tobira Therapeutics, Inc. - Dormant Developmental Projects,2015Tobira Therapeutics, Inc. - Discontinued Pipeline Products, 2015   List of FiguresTobira Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015Tobira Therapeutics, Inc. - Pipeline by Top 10 Target, 2015Tobira Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015Tobira Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015Tobira Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
                                                                
Note: Product cover images may vary from those shown




3 of 4





LOADING...







4 of 4






Note: Product cover images may vary from those shown








RELATED PRODUCTS 







INSYS Therapeutics, Inc. - Product Pipeline Review - 2016


 Company Profile
April 2016




FROM


€1335EUR$1,500USD£1,198GBP







Halozyme Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
May 2015
Region: Global




FROM


€1335EUR$1,500USD£1,198GBP







Argos Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1335EUR$1,500USD£1,198GBP







Galectin Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1335EUR$1,500USD£1,198GBP







Mersana Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
September 2015




FROM


€1335EUR$1,500USD£1,198GBP







Heron Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1335EUR$1,500USD£1,198GBP







Arno Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
August 2015




FROM


€1335EUR$1,500USD£1,198GBP







Aestus Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
March 2015




FROM


€1335EUR$1,500USD£1,198GBP







Protalix BioTherapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
November 2015




FROM


€1335EUR$1,500USD£1,198GBP







Io Therapeutics, Inc. - Product Pipeline Review - 2015


 Company Profile
December 2015




FROM


€1335EUR$1,500USD£1,198GBP








 close

Tobira Therapeutics, Inc. - Product Pipeline Review - 2015



 close

ASK A QUESTION

*Required Information
 
Product: Tobira Therapeutics, Inc. - Product Pipeline Review - 2015


YOUR QUESTION*







YOUR CONTACT DETAILS*

Title
Mr
Mrs
Dr
Miss
Ms
Prof




First Name




Last Name




Email Address




Country
Please Select
------------------------------
United States
United Kingdom
Germany
Canada
Australia
------------------------------
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica-Casey
Antarctica-Scott
Antigua and Barbuda
Argentina
Armenia
Aruba
Ascension Island
Ashmore and Cartier Islands
Atlantic East
Atlantic West
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burma
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Clipperton Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Curaco 
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Islas Malvinas)
Faroe Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Gaza Strip
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote d'Ivoire)
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Islands
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Islands
North Korea
Northern Ireland
Northern Marianas
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Christopher Nevis
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome
Saudi Arabia
Scotland
Senegal
Serbia
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Tahiti
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)
Venezuela
Vietnam
Virgin Islands
Wallis And Futuna
West Bank
West Indies
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




Phone Number



+1
+11
+1-242
+1-246
+1-264
+1-268
+1-284
+1-345
+1-441
+1-473
+1-649
+1-664
+1-670
+1-671
+1-684
+1-758
+1-767
+1-784
+1-787
+1-809
+1-868
+1-869
+1-876
+20
+212
+213
+216
+218
+220
+221
+222
+224
+225
+226
+227
+228
+229
+23
+230
+231
+232
+233
+234
+235
+236
+237
+238
+239
+240
+241
+242
+243
+244
+245
+247
+248
+249
+250
+251
+252
+253
+254
+255
+256
+257
+258
+260
+261
+263
+264
+265
+266
+267
+268
+269
+27
+284
+290
+291
+297
+298
+299
+30
+31
+32
+33
+34
+350
+351
+352
+353
+354
+355
+356
+357
+358
+359
+36
+370
+371
+372
+373
+374
+375
+376
+377
+378
+379
+380
+381
+382
+385
+386
+387
+389
+39
+40
+41
+420
+421
+423
+43
+44
+45
+46
+47
+48
+49
+500
+501
+502
+503
+504
+505
+506
+507
+509
+51
+52
+53
+54
+55
+56
+57
+58
+590
+591
+592
+593
+594
+595
+596
+597
+598
+599
+60
+61
+6101
+62
+63
+64
+65
+66
+670
+672
+673
+674
+675
+677
+678
+679
+680
+681
+682
+683
+685
+686
+687
+688
+689
+691
+692
+7
+81
+82
+84
+850
+852
+853
+855
+856
+86
+869
+871
+874
+880
+886
+90
+91
+92
+93
+94
+95
+960
+961
+962
+963
+964
+965
+966
+967
+968
+970
+971
+972
+973
+974
+975
+976
+977
+98
+992
+993
+994
+995
+996
+998












We request your telephone number so we can contact you in the event we have difficulty reaching you via email.
                    We aim to respond to all questions on the same business day.





 



 close

SEND TO A FRIEND

* Required Information
 FRIEND'S DETAILS

Full Name*




Email Address*




Message to friend




YOUR CONTACT DETAILS

Full Name*




Email Address*













 


 close

Request a Quote

 
Please complete the below form and click "send request" to obtain a pdf quotation and order form.
This document will be available for immediate download and will also be emailed to you.
            
* Required Information


YOUR ADDRESS

Address 1*




Address 2




Address 3




City*




Postal/ZIP Code




Country*
Please Select
------------------------------
United States
United Kingdom
Germany
Canada
Australia
------------------------------
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica-Casey
Antarctica-Scott
Antigua and Barbuda
Argentina
Armenia
Aruba
Ascension Island
Ashmore and Cartier Islands
Atlantic East
Atlantic West
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burma
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Clipperton Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Curaco 
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Islas Malvinas)
Faroe Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Gaza Strip
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote d'Ivoire)
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Islands
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Islands
North Korea
Northern Ireland
Northern Marianas
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Christopher Nevis
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome
Saudi Arabia
Scotland
Senegal
Serbia
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Tahiti
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)
Venezuela
Vietnam
Virgin Islands
Wallis And Futuna
West Bank
West Indies
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




State





YOUR DETAILS

Title*
Mr
Mrs
Dr
Miss
Ms
Prof




First Name*




Last Name*




Organisation*




Email Address*




Phone Number*



+1
+11
+1-242
+1-246
+1-264
+1-268
+1-284
+1-345
+1-441
+1-473
+1-649
+1-664
+1-670
+1-671
+1-684
+1-758
+1-767
+1-784
+1-787
+1-809
+1-868
+1-869
+1-876
+20
+212
+213
+216
+218
+220
+221
+222
+224
+225
+226
+227
+228
+229
+23
+230
+231
+232
+233
+234
+235
+236
+237
+238
+239
+240
+241
+242
+243
+244
+245
+247
+248
+249
+250
+251
+252
+253
+254
+255
+256
+257
+258
+260
+261
+263
+264
+265
+266
+267
+268
+269
+27
+284
+290
+291
+297
+298
+299
+30
+31
+32
+33
+34
+350
+351
+352
+353
+354
+355
+356
+357
+358
+359
+36
+370
+371
+372
+373
+374
+375
+376
+377
+378
+379
+380
+381
+382
+385
+386
+387
+389
+39
+40
+41
+420
+421
+423
+43
+44
+45
+46
+47
+48
+49
+500
+501
+502
+503
+504
+505
+506
+507
+509
+51
+52
+53
+54
+55
+56
+57
+58
+590
+591
+592
+593
+594
+595
+596
+597
+598
+599
+60
+61
+6101
+62
+63
+64
+65
+66
+670
+672
+673
+674
+675
+677
+678
+679
+680
+681
+682
+683
+685
+686
+687
+688
+689
+691
+692
+7
+81
+82
+84
+850
+852
+853
+855
+856
+86
+869
+871
+874
+880
+886
+90
+91
+92
+93
+94
+95
+960
+961
+962
+963
+964
+965
+966
+967
+968
+970
+971
+972
+973
+974
+975
+976
+977
+98
+992
+993
+994
+995
+996
+998











                                PO Number
                                (if applicable)







PRODUCT FORMAT




License
Format
Properties
Price




 
SINGLE USER Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is a single user license, allowing one specific user access to the product.
                                        

€1335EUR$1,500USD£1,198GBP





 
SITE LICENSE Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is a site license, allowing all users within a given geographical location of your organisation access to the product.
                                        

€2670EUR$3,000USD£2,395GBP





 
ENTERPRISEWIDE Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is an enterprise license, allowing all employees within your organisation access to the product.
                                        

€4005EUR$4,500USD£3,593GBP







* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.





 



























Tobira Therapeutics, Inc. - Product Pipeline Review - 2015

























 info@marketreportscenter.com
 +1-646-883-3044 (US) 24x7















LOGIN
SIGN UP














Facebook



Twitter



LinkedIn



Google +



MRC Blog



YouTube







Tobira Therapeutics, Inc. - Product Pipeline Review - 2015

Home >> Pharmaceuticals >> Global Markets Direct >> Tobira Therapeutics, Inc. - Product Pipeline Review - 2015



Report Details





Tobira Therapeutics, Inc. - Product Pipeline Review - 2015







SKU
GMDJUN191567


Category
Pharmaceuticals


Publisher
Global Markets Direct


Pages
33


Published
Jun-15





SKUGMDJUN191567
CategoryPharmaceuticals
PublisherGlobal Markets Direct
Pages33
Published OnJun-15

Request Discount
Pay by Wire/Invoice





Description
Table of Content
List of Figures
Request Sample




Description
Tobira Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Directs, Tobira Therapeutics, Inc. - Product Pipeline Review - 2015, provides an overview of the Tobira Therapeutics, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tobira Therapeutics, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Tobira Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Tobira Therapeutics, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Tobira Therapeutics, Inc.s pipeline products

Reasons to buy

- Evaluate Tobira Therapeutics, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Tobira Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Tobira Therapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Tobira Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tobira Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Tobira Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

News/Press Release

Precision Medicine: How the life science industry can improve outcomes through To achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option, researchers in drug R&D need to better understand and manage the reams of unstructured dat...Read More
Regenerative Medicine Market to Hit $53 billion by 2021 The current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021, as impact of Trump administration....Read More
7 Benefits of MicroneedlingMicroneedling: Hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your face....Read More



Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Tobira Therapeutics, Inc. Snapshot 5
Tobira Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Tobira Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Tobira Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Tobira Therapeutics, Inc. - Pipeline Products Glance 11
Tobira Therapeutics, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Tobira Therapeutics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Tobira Therapeutics, Inc. - Drug Profiles 14
(cenicriviroc mesylate + lamivudine + efavirenz) 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
(cenicriviroc mesylate + lamivudine) 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
cenicriviroc mesylate 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
REG-2 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
REG-3 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Tobira Therapeutics, Inc. - Pipeline Analysis 21
Tobira Therapeutics, Inc. - Pipeline Products by Target 21
Tobira Therapeutics, Inc. - Pipeline Products by Route of Administration 22
Tobira Therapeutics, Inc. - Pipeline Products by Molecule Type 23
Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action 24
Tobira Therapeutics, Inc. - Recent Pipeline Updates 25
Tobira Therapeutics, Inc. - Dormant Projects 29
Tobira Therapeutics, Inc. - Discontinued Pipeline Products 30
Discontinued Pipeline Product Profiles 30
REG-1 30
Tobira Therapeutics, Inc. - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33


List of Figures
List of Tables
Tobira Therapeutics, Inc., Key Information 5
Tobira Therapeutics, Inc., Key Facts 5
Tobira Therapeutics, Inc. - Pipeline by Indication, 2015 7
Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Tobira Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Tobira Therapeutics, Inc. - Phase II, 2015 11
Tobira Therapeutics, Inc. - Phase I, 2015 12
Tobira Therapeutics, Inc. - Preclinical, 2015 13
Tobira Therapeutics, Inc. - Pipeline by Target, 2015 21
Tobira Therapeutics, Inc. - Pipeline by Route of Administration, 2015 22
Tobira Therapeutics, Inc. - Pipeline by Molecule Type, 2015 23
Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 24
Tobira Therapeutics, Inc. - Recent Pipeline Updates, 2015 25
Tobira Therapeutics, Inc. - Dormant Developmental Projects,2015 29
Tobira Therapeutics, Inc. - Discontinued Pipeline Products, 2015 30
List of Figures
Tobira Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 7
Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Tobira Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 21
Tobira Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 22
Tobira Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 23
Tobira Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 24







Please Select License Type






Single User Electronic PDF 
$ 1,500.00


Site User Electronic PDF 
$ 3,000.00


Enterprise Wide Electronic PDF 
$ 4,500.00



ADD TO CART

BUY NOW






Related Reports




 Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Urinary Incontinence - Pipeline Review, H2 2017 ICT Investment Trends in China: Enterprises initiatives inclined towards digitization fuelling ICT investments Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse Global Veterinary Therapeutics Market Research Report 2017 










Request Sample






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Request Discount






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Pay by Wire/Invoice






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
















Single User Electronic PDF
Site User Electronic PDF
Enterprise Wide Electronic PDF
CD ROM
Hard Copy














SEND










Request Quote






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND









Market Reports Center © Copyright 2017 All rights reserved.









































Tobira Therapeutics, Inc.: Private Company Information - Bloomberg









































  





















































































July 23, 2017 7:10 PM ET
Biotechnology

Company Overview of Tobira Therapeutics, Inc.



Snapshot People




Company Overview
Tobira Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat liver disease, inflammation, fibrosis, and HIV. Its lead product candidate includes cenicriviroc, an immunomodulator and dual inhibitor of CCR2 and CCR5, which is in Phase 2a study for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis disease; and Phase 2b study for HIV. The company was founded in 2006 and is headquartered in South San Francisco, California. As of November 1, 2016, Tobira Therapeutics, Inc. operates as a subsidiary of Allergan plc.


701 Gateway BoulevardSuite 300South San Francisco, CA 94080United StatesFounded in 200619 Employees



Phone: 650-741-6625

www.tobiratherapeutics.com







Key Executives for Tobira Therapeutics, Inc.




Dr. Laurent Fischer M.D.


      	Chief Executive Officer
      


Age: 53
        







Mr. Robert D. Bailey


      	President
      


Age: 54
        







Mr. Christopher Peetz


      	Chief Financial Officer and Head of Corporate Development
      


Age: 38
        







Ms. Helen Jenkins MA


      	Chief Operating Officer
      


Age: 53
        







Dr. Eric A. Lefebvre M.D.


      	Chief Medical Officer
      


Age: 53
        




Compensation as of Fiscal Year 2017. 

Tobira Therapeutics, Inc. Key Developments

Tobira Therapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 03:45 PM
Dec 15 16
Tobira Therapeutics, Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 03:45 PM. Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States. Speakers: Laurent Fischer, Chief Executive Officer.


Tobira Therapeutics Files Form 15
Nov 14 16
Tobira Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.001 par value under the Securities Exchange Act of 1934, as amended.



Tobira Therapeutics, Inc. Announces Executive Changes
Nov 1 16
On June 3, 2015, Tobira entered into a sales agreement with Cowen and Company, LLC, pursuant to which Tobira could issue and sell, from time to time through Cowen, shares of Tobira's common stock having an aggregate offering price of up to $40.0 million. Effective October 31, 2016, Tobira terminated the Sales Agreement. Pursuant to the Merger Agreement, as of the Effective Time, Carol L.  Brosgart, M.D., Jeffrey H. Cooper, Laurent Fischer, M.D., Andrew J.  Fromkin, Patrick Heron, Pierre Legault, Gwen A. Melincoff, Dennis Podlesak and Eckard Weber, M.D., each resigned and ceased to be directors of Tobira and members of any committee of Tobira's Board of Directors. Pursuant to the Merger Agreement, as of the Effective Time, the directors and officers of Purchaser immediately prior to the Effective Time became the directors and officers of the Surviving Corporation. The directors of Purchaser immediately prior to the effective time were Kira Schwartz and Sigurd Kirk. As of the Effective Time, Tobira's Board of Directors appointed A. Robert D. Bailey as President, Stephen Kaufhold as Treasurer and Kira Schwartz as Secretary.


Similar Private Companies By Industry



Company Name
Region



 20n Labs, Inc. United States 23andMe, Inc. United States 2C Tech Corporation, Inc. United States 3-V Biosciences, Inc. United States 3Bar Biologics Inc. United States




Recent Private Companies Transactions



TypeDate
Target





Merger/Acquisition

			      September 20, 2016
			    
--





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States Bertelsmann AG Europe The Advertising Council, Inc. United States Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Tobira Therapeutics, Inc., please visit www.tobiratherapeutics.com.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close




























Tobira Therapeutics, Inc. - Product Pipeline Review - 2014 : ReportsnReports


























 



 Market Research Report 


Welcome Guest  |  
					Register/Login | 
					Contact Us | 
					About Us
  




+ 1 888 391 5441








Advanced Search










Home › 
                    
                        Biotechnology › 
                     Report Detail 



 Tobira Therapeutics, Inc. - Product Pipeline Review - 2014





						Published:  December 2014
						No. of Pages: 25

Price 
							
Single User License: US $ 1500
Corporate User License: US $ 4500
  
							


















Report Description
Table of Contents
 

Inquire Before Buying 










Global Markets Direct’s, ‘Tobira Therapeutics, Inc. Product Pipeline Review 2014’, provides an overview of the Tobira Therapeutics, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Tobira Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of Tobira Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Tobira Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the Tobira Therapeutics, Inc.’s pipeline productsReasons to buyEvaluate Tobira Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Tobira Therapeutics, Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Tobira Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Tobira Therapeutics, Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Tobira Therapeutics, Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Tobira Therapeutics, Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues





                               Tobira Therapeutics, Inc. - Product Pipeline Review - 2014                            


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Tobira Therapeutics, Inc. Snapshot 4Tobira Therapeutics, Inc. Overview 4Key Information 4Key Facts 4Tobira Therapeutics, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Tobira Therapeutics, Inc. - Pipeline Review 7Pipeline Products by Stage of Development 7Pipeline Products - Monotherapy 8Pipeline Products - Combination Treatment Modalities 9Tobira Therapeutics, Inc. - Pipeline Products Glance 10Tobira Therapeutics, Inc. - Clinical Stage Pipeline Products 10Phase II Products/Combination Treatment Modalities 10Tobira Therapeutics, Inc. - Early Stage Pipeline Products 11Preclinical Products/Combination Treatment Modalities 11Tobira Therapeutics, Inc. - Drug Profiles 12(cenicriviroc + lamivudine + efavirenz) 12Product Description 12Mechanism of Action 12R&D Progress 12(cenicriviroc + lamivudine) 13Product Description 13Mechanism of Action 13R&D Progress 13cenicriviroc 14Product Description 14Mechanism of Action 14R&D Progress 14Tobira Therapeutics, Inc. - Pipeline Analysis 16Tobira Therapeutics, Inc. - Pipeline Products by Target 16Tobira Therapeutics, Inc. - Pipeline Products by Route of Administration 17Tobira Therapeutics, Inc. - Pipeline Products by Molecule Type 18Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action 19Tobira Therapeutics, Inc. - Recent Pipeline Updates 20Tobira Therapeutics, Inc. - Dormant Projects 22Tobira Therapeutics, Inc. - Locations And Subsidiaries 23Head Office 23Other Locations & Subsidiaries 23Appendix 24Methodology 24Coverage 24Secondary Research 24Primary Research 24Expert Panel Validation 24Contact Us 25Disclaimer 25List of TablesTobira Therapeutics, Inc., Key Information 4Tobira Therapeutics, Inc., Key Facts 4Tobira Therapeutics, Inc. - Pipeline by Indication, 2014 6Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2014 7Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8Tobira Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 9Tobira Therapeutics, Inc. - Phase II, 2014 10Tobira Therapeutics, Inc. - Preclinical, 2014 11Tobira Therapeutics, Inc. - Pipeline by Target, 2014 16Tobira Therapeutics, Inc. - Pipeline by Route of Administration, 2014 17Tobira Therapeutics, Inc. - Pipeline by Molecule Type, 2014 18Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 19Tobira Therapeutics, Inc. - Recent Pipeline Updates, 2014 20Tobira Therapeutics, Inc. - Dormant Developmental Projects,2014 22Tobira Therapeutics, Inc., Other Locations 23List of FiguresTobira Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 6Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2014 7Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 8Tobira Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 16Tobira Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 17Tobira Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 18Tobira Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 19




 

Published By: 
                            Global Markets Direct 

Product Code:
                            Global Markets Direct10266 







                        Did you find what you are/were looking for
                        ?
                        If not, read below and browse through other relevant pages for similar market research
                        reports OR get in touch with us through the form/contact info in your right navigation
                        panel and well share relevant market report titles for you to explore.
					


                            Related Reports:
                        





 Asia-Pacific Enzymes Market Report 2017						
						In this report, the Asia-Pacific Enzymes market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into sev...  
 Global Cell-based Assays Market Research Report 2017						
						In this report, the global Cell-based Assays market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into sever...  
 Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Cell Culture Market 2017 Forecast to 2022						
						Cell culture is the process by which cells are grown under controlled conditions, generally outside of their natural environment. Cell culture is one of the major tools used in cellular and molecular biology, since it provides excellent model systems...  
 2017-2022 United States DNA Microarray Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The DNA Microarray market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from...  
 2017-2022 Philippines DNA Microarray Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The DNA Microarray market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2...  
 2017-2022 Malaysia DNA Microarray Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The DNA Microarray market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016...  
 2017-2022 Japan DNA Microarray Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The DNA Microarray market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to...  
 2017-2022 India DNA Microarray Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The DNA Microarray market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to...  
 2017-2022 Global Top Countries DNA Microarray Market Report						
						"This report will be delivered in 2-3 business days after the order is placed."

The Global DNA Microarray market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2...  
 2017-2022 China DNA Microarray Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The DNA Microarray market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to...  









 







  
   



Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
                            
Upto 24 hrs - working days
Upto 48 hrs max - weekends and public holidays






Research Support / Custom Research
                    If this business study does not have the data and information analysis you need,
                    contact us with your research requirements. We explore available market research
                    reports to map your needs and share report titles with you. Alternatively, we can
                    also offer custom research that suits your budget and timelines. Share your information
                    requirements here.



                        Connect With Us





 









































Email: sales@reportsandreports.com
Call : + 1 888 391 5441 


 



Home
Category
Publisher
Country
Latest Reports
Markets
Discounted Reports
Upcoming Reports
Contact Us



Subscription Option



                                Using our subscription option, you get access to market research reports and industry data of  Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.


More about our Subscription option 




Report Alerts

Get Email alerts about market research reports from industries and publishers of
							your interest:







Please Enter a Valid Email ID
Thank you! You have successfully subscribed to our Report Alerts!






 







 Avail upto 25% Discount on below Publisher Reports.

Technavio
Azoth Analytics







					© 2017 ReportsnReports. All rights reserved. Disclamer. 
						Privacy Policy , Terms and Conditions
					| Our Market Research Blog | Sitemap

Feeds: RSS | Latest Reports































Page not found | Market Research Reports® Inc.

















Skip to main content









 








Home
FAQs
Contact Us
Become Publisher
Blog
 





0 items $0.00 











Search form

Search this site 
 

Search



 










You are here: Home  global markets direct tobira therapeutics inc product pipeline review 2012 









Page not found

×

Error message
The page you requested does not exist. For your convenience, a search was performed using the query global markets direct tobira therapeutics inc product pipeline review 2012.





Enter terms 
 

Search



Your search for "" gave back 859841 results.






Tobira Therapeutics, Inc. - Product Pipeline Review - 2015




Tobira Therapeutics, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct’s, ‘Tobira Therapeutics, Inc. - Product Pipeline Review -...



Catalog: 

Company Reports (Pharma & Healthcare)




Global Markets Direct




Global






June 2015




Price: $1,500.00 









C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2016




C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C...



Catalog: 

Diseases




Global Markets Direct




Global






October 2016




Price: $3,500.00 









C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016




C-C Chemokine Receptor Type 5 (C-C CKR-5 or CHEMR13 or HIV-1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2016 Summary Global Markets...



Catalog: 

Diseases




Global Markets Direct




Global






June 2016




Price: $3,500.00 









Primary Sclerosing Cholangitis - Pipeline Review, H2 2016




Primary Sclerosing Cholangitis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H2 2016...



Catalog: 

Diseases




Global Markets Direct




Global






July 2016




Price: $2,000.00 









Peritonitis - Pipeline Review, H1 2016




Peritonitis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Peritonitis - Pipeline Review, H1 2016’, provides an overview of the...



Catalog: 

Diseases




Global Markets Direct




Global






May 2016




Price: $2,000.00 









Primary Sclerosing Cholangitis - Pipeline Review, H1 2016




Primary Sclerosing Cholangitis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H1 2016...



Catalog: 

Diseases




Global Markets Direct




Global






February 2016




Price: $2,000.00 









Kidney Fibrosis - Pipeline Review, H2 2016




Kidney Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney...



Catalog: 

Diseases




Global Markets Direct




Global






October 2016




Price: $2,000.00 









Kidney Fibrosis - Pipeline Review, H1 2016




Kidney Fibrosis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Kidney Fibrosis - Pipeline Review, H1 2016’, provides an overview of the...



Catalog: 

Diseases




Global Markets Direct




Global






April 2016




Price: $2,000.00 









Kidney Fibrosis - Pipeline Review, H1 2015




Kidney Fibrosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Kidney Fibrosis - Pipeline Review, H1 2015’, provides an overview of the...



Catalog: 

Diseases




Global Markets Direct




Global






April 2015




Price: $2,000.00 









Diabetic Nephropathy - Pipeline Review, H2 2016




Diabetic Nephropathy - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2016’, provides an...



Catalog: 

Diseases




Global Markets Direct




Global






August 2016




Price: $2,000.00 









Diabetic Nephropathy - Pipeline Review, H1 2016




Diabetic Nephropathy - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H1 2016’, provides an...



Catalog: 

Diseases




Global Markets Direct




Global






February 2016




Price: $2,000.00 









Fatty Liver Disease - Pipeline Review, H1 2015




Fatty Liver Disease - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Fatty Liver Disease - Pipeline Review, H1 2015’, provides an...



Catalog: 

Diseases




Global Markets Direct




Global






March 2015




Price: $2,000.00 









Diabetic Nephropathy - Pipeline Review, H2 2015




Diabetic Nephropathy - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Diabetic Nephropathy - Pipeline Review, H2 2015’, provides an...



Catalog: 

Diseases




Global Markets Direct




Global






November 2015




Price: $2,000.00 









Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015




Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015...



Catalog: 

Diseases




Global Markets Direct




Global






October 2015




Price: $2,000.00 









Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015




Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) -...



Catalog: 

Diseases




Global Markets Direct




Global






July 2015




Price: $2,000.00 


1
2
3
4
5
6
7
8
9
…
next
 




Filter By Report Date

Past year (493933) Apply Past year filter 
Past month (19753) Apply Past month filter 
 


Filter By Industry

Chemicals (292056) Apply Chemicals filter Specialty Chemicals (262557) Apply Specialty Chemicals filter 
Country Overview (Chemicals) (133452) Apply Country Overview (Chemicals) filter 
Reagents (17401) Apply Reagents filter 
Manufacturing (Chemicals) (5196) Apply Manufacturing (Chemicals) filter 

Industry & Manufacturing (206389) Apply Industry & Manufacturing filter Machinery (145903) Apply Machinery filter 
Country Overview (Industry & Manufacturing) (82276) Apply Country Overview (Industry & Manufacturing) filter 
Manufacturers (39071) Apply Manufacturers filter 
Construction (23371) Apply Construction filter 
Company Reports (Industry & Manufacturing) (17064) Apply Company Reports (Industry & Manufacturing) filter 
Metals (6719) Apply Metals filter 
Agriculture (5732) Apply Agriculture filter 
Aerospace (4690) Apply Aerospace filter 

Pharma & Healthcare (100772) Apply Pharma & Healthcare filter Healthcare (64384) Apply Healthcare filter 
Country Overview (Pharma & Healthcare) (38626) Apply Country Overview (Pharma & Healthcare) filter 
Medical Devices (33984) Apply Medical Devices filter 
Company Reports (Pharma & Healthcare) (7869) Apply Company Reports (Pharma & Healthcare) filter 
Biotechnology (7732) Apply Biotechnology filter 
Diagnostics (6998) Apply Diagnostics filter 
Deals & Alliances (Pharma & Healthcare) (6497) Apply Deals & Alliances (Pharma & Healthcare) filter 

Computing & Electronics (73446) Apply Computing & Electronics filter Electrical Products (59429) Apply Electrical Products filter 
Electrical Components (34254) Apply Electrical Components filter 
Country Overview (Computing & Electronics) (28688) Apply Country Overview (Computing & Electronics) filter 
IT Services (5258) Apply IT Services filter 

Consumer & Retail (54624) Apply Consumer & Retail filter Consumer Services (30993) Apply Consumer Services filter 
Country Overview (Consumer & Retail) (24678) Apply Country Overview (Consumer & Retail) filter 
House & Home (7561) Apply House & Home filter 
Cosmetics & Personal Care (5320) Apply Cosmetics & Personal Care filter 

Food & Beverages (28533) Apply Food & Beverages filter Food (23912) Apply Food filter 
Country Overview (Food & Beverages) (15927) Apply Country Overview (Food & Beverages) filter 

Automotive (28242) Apply Automotive filter Components (25149) Apply Components filter 
Country Overview (Automotive) (11180) Apply Country Overview (Automotive) filter 

Banking & Finance (25384) Apply Banking & Finance filter Investments (10175) Apply Investments filter 
Securities Brokers & Traders (10096) Apply Securities Brokers & Traders filter 
Capital Markets (10006) Apply Capital Markets filter 
Country Overview (Banking & Finance) (10006) Apply Country Overview (Banking & Finance) filter 
Strategy (Banking & Finance) (10006) Apply Strategy (Banking & Finance) filter 
Insurance (9471) Apply Insurance filter 

Energy & Utilities (24075) Apply Energy & Utilities filter Company Reports (Energy & Utilities) (11627) Apply Company Reports (Energy & Utilities) filter 
Utilities (5930) Apply Utilities filter 
Country Overview (Energy & Utilities) (5823) Apply Country Overview (Energy & Utilities) filter 

Business & Government (8549) Apply Business & Government filter 
 


Filter By Country

Global (495256) Apply Global filter 
Asia Pacific (228808) Apply Asia Pacific filter China (177181) Apply China filter 
Japan (12202) Apply Japan filter 
India (12038) Apply India filter 
Australia (3656) Apply Australia filter 
Malaysia (2018) Apply Malaysia filter 
South Korea (1946) Apply South Korea filter 
Vietnam (1799) Apply Vietnam filter 
Philippines (1513) Apply Philippines filter 
Indonesia (1284) Apply Indonesia filter 
Thailand (1231) Apply Thailand filter 
Singapore (1162) Apply Singapore filter 

North America (126828) Apply North America filter USA (112703) Apply USA filter 
Canada (6539) Apply Canada filter 

Europe (117735) Apply Europe filter United Kingdom (7761) Apply United Kingdom filter 
Germany (3827) Apply Germany filter 
France (2994) Apply France filter 
Italy (2182) Apply Italy filter 
Spain (1977) Apply Spain filter 
Turkey (1862) Apply Turkey filter 
Russian Federation (1833) Apply Russian Federation filter 
Netherlands (1757) Apply Netherlands filter 
Sweden (1733) Apply Sweden filter 
Norway (1496) Apply Norway filter 
Switzerland (1492) Apply Switzerland filter 
Poland (1480) Apply Poland filter 
Belgium (1396) Apply Belgium filter 
Denmark (1353) Apply Denmark filter 
Finland (1334) Apply Finland filter 
Ireland (1280) Apply Ireland filter 
Austria (1256) Apply Austria filter 
Czech Republic (1113) Apply Czech Republic filter 
Greece (1105) Apply Greece filter 
Portugal (1058) Apply Portugal filter 
Romania (947) Apply Romania filter 

Africa (19714) Apply Africa filter South Africa (1394) Apply South Africa filter 

Middle East (19456) Apply Middle East filter 
South America (13955) Apply South America filter Brazil (1974) Apply Brazil filter 
Mexico (1969) Apply Mexico filter 
Argentina (1133) Apply Argentina filter 

Asia (3384) Apply Asia filter 
Oceania (2060) Apply Oceania filter 
Central America (1792) Apply Central America filter 
Eurasia (1784) Apply Eurasia filter 
Central Asia (1454) Apply Central Asia filter 
 









Clients Who Trust Us

 











Need tailor made market research solution? We can help you with that too.

Contact Us










About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.
We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.





Contact Us


Market Research Reports, Inc

















16192 Coastal Hwy
Lewes, DE 19958, USA
 USA: +1-302-703-9904
 India: +91-8762746600
 marketresearchreports
[email protected]
 




User login


Username *
 


Password *
 

Create new account
Request new password


Log in
 




Latest Blog Posts



  
 Investment Opportunities in Taiwan: Semiconductor, Chemical and Consumer Goods will Lead the Pack 

 Global Investment Opportunities in Ports and Terminals 
 
 


Stay Connected







 



Sign up to our newsletter:
Email Address *
 



Subscribe
 





 




Research Industries

Home
Automotive
Banking & Finance
Business & Government
Chemicals
Computing & Electronics
Consumer & Retail
Energy & Utilities
Food & Beverages
Industry & Manufacturing
Marketing & Advertising
Media
Pharma & Healthcare
Telecom
Transport
Travel & Leisure
 









Our Company

About Us
Publications By Country
FAQs
Privacy Policy
Terms & Conditions
 







© Copyright 2010-17 Market Research Reports, Inc.. All Rights Reserved. M Market Research Reports and the M Market Research Reports Logo are registered trademarks of Market Research Reports, Inc.
Disclaimer: Market Research Reports, Inc. has no affiliation to, and is not associated with any other website(s) or organization(s). We offer syndicated research reports (like country analysis, SWOT analysis, competitive intelligence, industry reports, company reports and market analysis & trends reports) and custom market research from our website MarketResearchReports.com only.
If you are looking for a market research solution for your research requirements, please begin your search using the search box on top of this page or use our chat system to speak to our market research consultants or directly write to us.
 











Tobira Therapeutics, Inc. - Product Pipeline Review - 2015



























Sales and support:
        +44 20 8123 2220 (UK)
        +1 732 587 5005 (US)
info@marketpublishers.com





Business & Finance

Retail






Retail


Consumer Goods


Food & Beverage







Industry

Chemicals

IT & Technology

Life Sciences






Medical Devices
Anesthesia & Respiratory
Cardiovascular Devices
Dental
Diabetes Care
Diagnostic Equipment
Drug Delivery
Endoscopy
Ear, Nose & Throat (ENT)
Healthcare Equipment/Supplies Company Reports
Implants
Neurology
Orthopedic
Ophthalmic
Surgical Equipment
Wound Closure
Other Medical Devices


Biotechnology
Biomarkers
Biomaterials
Biosimilars
Stem Cell

Diagnostics & Diseases
In Vitro Diagnostics
Incontinence
Cancer
Cardiovascular
Diabetes
Hepatitis


Healthcare
Healthcare Services Company Reports
Ear Care
Eye Care
Hospital
Medicated Skin Care
Therapy
Wound Care


Pharmaceuticals
Clinical Trial
Drug Stores
Drugs
Pharmaceuticals Company Reports
Vaccines

Medical Products
Veterinary






Services



About
Faq
 My Cart


 











Market Reports
Press-Releases
Events
About Us
Terms & Conditions
Customer FAQ




Market Research Reports

Life Sciences

Healthcare

Therapy





Tobira Therapeutics, Inc. - Product Pipeline Review - 2015





Date:
June 24, 2015



Pages:
33


Price:




US$ 1,500.00




License             [?]:


Single-User License - US$ 1,500.00
Site License - US$ 3,000.00
 Enterprisewide License - US$ 4,500.00




Publisher:
Global Markets Direct


Report type:
Strategic Report


Delivery:

E-mail Delivery (PDF)


ID:
T7FEFE748E8EN



        Leaflet:
    

Download PDF Leaflet






















Abstracts
Contents
List of Tables
List of Figures





Tobira Therapeutics, Inc. - Product Pipeline Review - 2015SummaryGlobal Markets Direct’s, ‘Tobira Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Tobira Therapeutics, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Tobira Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of Tobira Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Tobira Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the Tobira Therapeutics, Inc.’s pipeline productsReasons to buyEvaluate Tobira Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Tobira Therapeutics, Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Tobira Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Tobira Therapeutics, Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Tobira Therapeutics, Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Tobira Therapeutics, Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues



    Tobira Therapeutics, Inc. SnapshotTobira Therapeutics, Inc. OverviewKey InformationKey FactsTobira Therapeutics, Inc. - Research and Development OverviewKey Therapeutic AreasTobira Therapeutics, Inc. - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyPipeline Products - Combination Treatment ModalitiesTobira Therapeutics, Inc. - Pipeline Products GlanceTobira Therapeutics, Inc. - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesPhase I Products/Combination Treatment ModalitiesTobira Therapeutics, Inc. - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesTobira Therapeutics, Inc. - Drug Profiles(cenicriviroc mesylate + lamivudine + efavirenz)Product DescriptionMechanism of ActionR&D Progress(cenicriviroc mesylate + lamivudine)Product DescriptionMechanism of ActionR&D Progresscenicriviroc mesylateProduct DescriptionMechanism of ActionR&D ProgressREG-2Product DescriptionMechanism of ActionR&D ProgressREG-3Product DescriptionMechanism of ActionR&D ProgressTobira Therapeutics, Inc. - Pipeline AnalysisTobira Therapeutics, Inc. - Pipeline Products by TargetTobira Therapeutics, Inc. - Pipeline Products by Route of AdministrationTobira Therapeutics, Inc. - Pipeline Products by Molecule TypeTobira Therapeutics, Inc. - Pipeline Products by Mechanism of ActionTobira Therapeutics, Inc. - Recent Pipeline UpdatesTobira Therapeutics, Inc. - Dormant ProjectsTobira Therapeutics, Inc. - Discontinued Pipeline ProductsDiscontinued Pipeline Product ProfilesREG-1Tobira Therapeutics, Inc. - Locations And SubsidiariesHead OfficeAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer


LIST OF TABLESTobira Therapeutics, Inc., Key InformationTobira Therapeutics, Inc., Key FactsTobira Therapeutics, Inc. - Pipeline by Indication, 2015Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015Tobira Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015Tobira Therapeutics, Inc. - Phase II, 2015Tobira Therapeutics, Inc. - Phase I, 2015Tobira Therapeutics, Inc. - Preclinical, 2015Tobira Therapeutics, Inc. - Pipeline by Target, 2015Tobira Therapeutics, Inc. - Pipeline by Route of Administration, 2015Tobira Therapeutics, Inc. - Pipeline by Molecule Type, 2015Tobira Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015Tobira Therapeutics, Inc. - Recent Pipeline Updates, 2015Tobira Therapeutics, Inc. - Dormant Developmental Projects,2015Tobira Therapeutics, Inc. - Discontinued Pipeline Products, 2015


LIST OF FIGURESTobira Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015Tobira Therapeutics, Inc. - Pipeline by Stage of Development, 2015Tobira Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015Tobira Therapeutics, Inc. - Pipeline by Top 10 Target, 2015Tobira Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015Tobira Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015Tobira Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
        
        
Skip to top




MORE PUBLICATIONS


Stemline Therapeutics, Inc. - Product Pipeline Review - 2016
US$ 1,500.00
Aug, 2016 · 49 pages


Acorda Therapeutics, Inc. - Product Pipeline Review - 2015
US$ 1,500.00
Jun, 2015 · 48 pages








Ask Your Question
Tobira Therapeutics, Inc. - Product Pipeline Review - 2015







Company name*:



Contact person*:



Phone/fax*:



Email*:




 Request invoice


Your enquiry:




				Please click on a Check Box below to confirm you are not a robot:
					


























Market Reports


All Categories  Biotechnology Biomarkers Biomaterials Biosimilars Stem Cell  Diagnostics & Diseases In Vitro Diagnostics Incontinence Cancer Cardiovascular Diabetes Hepatitis  Healthcare Healthcare Services Company Reports Ear Care Eye Care Hospital Medicated Skin Care Therapy Wound Care  Medical Devices Anesthesia & Respiratory Cardiovascular Devices Dental Devices Diabetes Care Diagnostic Equipment Drug Delivery Endoscopy Ear, Nose & Throat (ENT) Devices Healthcare Equipment/Supplies Company Reports Neurology Orthopedic Devices Ophthalmic Surgical Equipment Wound Closure Other Medical Devices  Medical Products Pharmaceuticals Clinical Trials Drug Stores Drugs Pharmaceuticals Company Reports Vaccines  Veterinary 












Sales and support:
                    +44 20 8123 2220
            +1 732 587 5005
info@marketpublishers.com
  © 2006-2016 MarketPublishers.com


About Us
Our Clients
Our Publishers
Customer FAQ


Market Reports
New Publications
Reports by Regions
Press-Releases


Terms & Conditions
Privacy Policy
Return Policy
Affiliate Program


Join as Publisher

Follow Us:






















Therapy Market Research Reports & Industry Analysis


























Sales and support:
        +44 20 8123 2220 (UK)
        +1 732 587 5005 (US)
info@marketpublishers.com





Business & Finance






Finance Services
Banking
Cards
Credit & Loans
Financial Company Reports
Investment
Mortgage
Payment
Other Financial Services


Insurance
General Insurance
Health Insurance
Insurance Company Reports
Life Insurance
Property Insurance
Reinsurance
Auto Insurance


Business Services
Accounting & Tax Services
Advertising
Brokerage
Business Support
Business Services Company Reports
Consulting
Diversified Services Company Reports
Franchise
Wealth Management


Company Reports
Business Survey
Real Estate





Retail






Retail
Cash & Carry
Convenience Stores
Department Stores
Duty Free
Hypermarkets & Supermarkets
Online Retail
Retail Company Reports
Service Station Retail
Specialist Store
Wholesale 

Consumer Goods
Consumer Products Company Reports
Cosmetics & Hygiene Products
Furnishing
Jewelry & Accessories
Household Products
Pet Products
Sporting Goods & Equipment
Stationery
Textile & Leather
Tobacco
Toys & Games 

Food & Beverage
Alcoholic Drinks
Soft Drinks
Food
Food & Beverage Company Reports







Industry






Agriculture
Agribusiness
Agricultural Products
Animal Husbandry
Fisheries
Fertilizers
Gardening & Forestry

Construction
Building Materials
Building Products Company Reports
Commercial Construction
Engineering & Construction Services Company Report
Industrial construction
Infrastructure
Residential Construction


Energy
Alternative Energy
Batteries & Accumulators
Electric Power
Energy Company Reports
Nuclear Power
Smart Grid
Thermal Power

Metallurgy
Alkali Metals
Ferrous Metallurgy
Metal Alloys
Metal products
Metals & Mining Company Reports
Non-Ferrous Metallurgy
Precious Metals
Rare-Earth Metals
Uranous Metals (Actinoid)


Mineral Raw Materials
Building Raw Materials & Fillers
Conglomerates Company Reports
Fossil Fuel
Nonmetallic Minerals
Metalloids
Ores
Precious & Semi-Precious Stones


Machinery & Equipment
Defence & Security
Packaging Industry
Publishing Industry
Pulp & Paper
Vehicle
Other Industries






Chemicals






Organic Chemicals
Alcohols
Alkenes (Olefins)
Ethers
Organic Acids & Derivatives
Aldehydes & Ketones
Amines
Halogenated
Polymers
Alkanes
Benzene & Derivatives
Isocyanates


Inorganic Chemicals
Alkali
Inorganic Salts
Non-Metallic Oxides
Inorganic Acids
Metal Oxides


Chemical Company Reports
Chemical Reports by CAS Number
Composite Materials
Oils & Lubricants






IT & Technology






Consumer Electronics
Audio & Video Equipment
GPS Navigation
Mobile Phones & Smartphones
PC & Notebooks
Photography


Hardware
Computer Hardware
Computers & Electronic Equipment Company Reports
Data Storage
Networking Hardware


Software
Application Software
Operating System
Programming Software
Software Development
Software & Technology Services Company Reports
Video Games


Telecommunications
Broadband
Communication Services Company Reports
Internet
Mobile
Networks
Telecom Equipment
Wireless Technology






Life Sciences






Medical Devices
Anesthesia & Respiratory
Cardiovascular Devices
Dental
Diabetes Care
Diagnostic Equipment
Drug Delivery
Endoscopy
Ear, Nose & Throat (ENT)
Healthcare Equipment/Supplies Company Reports
Implants
Neurology
Orthopedic
Ophthalmic
Surgical Equipment
Wound Closure
Other Medical Devices


Biotechnology
Biomarkers
Biomaterials
Biosimilars
Stem Cell

Diagnostics & Diseases
In Vitro Diagnostics
Incontinence
Cancer
Cardiovascular
Diabetes
Hepatitis


Healthcare
Healthcare Services Company Reports
Ear Care
Eye Care
Hospital
Medicated Skin Care
Therapy
Wound Care


Pharmaceuticals
Clinical Trial
Drug Stores
Drugs
Pharmaceuticals Company Reports
Vaccines

Medical Products
Veterinary






Services






Freight & Trucking
Air Freight
Freight & Trucking Company Reports
Rail Freight
Road Freight
Water Freight


Media & Entertainment
Casino and Gaming
Cinema & Theater
Magazine & Newspaper
Media Company Reports
Music
Social Media
Television & Radio


Food Service
Fast Food
Restaurants
Restaurants & Leisure Company Reports
Pub & Bar


Consumer Services
Education
Hotels
Legal Services
Logistics
Post & Courier
Recruitment
Rent
Sports & Fitness Center
Travel & Leisure
Other Services








About
Faq
 My Cart


 











Market Reports
Press-Releases
Events
About Us
Terms & Conditions
Customer FAQ




Market Research Reports

Life Sciences

Healthcare

Therapy








Therapy Market Research Reports & Industry Analysis


Defined as treatment of disabilities/illnesses (physical and mental), therapy represents an essential branch of medicine.  This term is widely used by psychologists to describe the session between them and patients. Depending on an illness, different therapies types are applied. Therapies may be aimed at the prevention of the disease occurrence, stopping its further progress or preventing an outbreak. They may be also used to improve a patient’s comfort.  
Therapies are classified on the basis of energy (e.g. phototherapy and thermotherapy), human interaction (for instance, psychotherapy and psychotherapy) and matter (e.g. gene therapy and biotherapy), etc. 
The Catalogue is an unprecedented source of research reports analyzing the therapy market in detail. The reports uncover the market sizing and segmentation, its present standing and future prospects. The research studies investigate the competitive environment and contain majors’ profiles. Market igniters and limiters are scrutinized, and trends and future opportunities are unveiled in the reports.





All Regions
Global
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Africa
                                                                                                                                                                                                                                                                                                                                        --Algeria
                                                                                                                                                                                                                                                                                                                                                                                                                    --Cameroon
                                                                                                                                                                                                                                                                                                                                                                                                                    --Egypt
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        --Kenya
                                                                                                                                                                                                                                                                                                        --Morocco
                                                                                                                                                        --Nigeria
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            --South Africa
                                                                                                                                                                                                                                                                    --Tunisia
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                East Asia and Pacific
                                                                                                                                                                                                                                                                                                                                                                                                                --Australia
                                                                                                                                                                                                                                                                                                                                                                                                                    --China
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        --Hong Kong
                                                                                                                    --India
                                                                                --Indonesia
                                                                                                                                                        --Japan
                                                                                                                                                        --South Korea
                                                                                                                                                                                            --Malaysia
                                                                                                                                                                                            --New Zealand
                                                                                                                                                        --Pakistan
                                                                                                                    --Philippines
                                                                                                                                                                                                                                --Singapore
                                                                                                                                                                                                                                                                                                        --Taiwan
                                                                                --Thailand
                                                                                                                                                                                                                                                                                                        --Vietnam
                                                                                                                                                                                                                                                                                                                                                                                                                                                        Europe
                                                                                                                                                    --Germany
                                                                                --Russia
                                                                                                                    --Belarus
                                                                                --Ukraine
                                                                                                                                                                                            --Austria
                                                                                                                    --Belgium
                                                                                                                    --Bosnia and Herzegovina
                                                                                                                    --Bulgaria
                                                                                                                                                                                                                                                                    --Croatia
                                                                                --Czech Republic
                                                                                --Denmark
                                                                                                                                                                                            --Estonia
                                                                                --Finland
                                                                                --France
                                                                                                                    --Greece
                                                                                                                                                        --Hungary
                                                                                                                                                        --Ireland
                                                                                --Italy
                                                                                                                                                                                                                                --Latvia
                                                                                --Lithuania
                                                                                --Macedonia
                                                                                                                                                                                            --Netherlands
                                                                                                                                                        --Norway
                                                                                                                                                                                            --Poland
                                                                                --Portugal
                                                                                --Romania
                                                                                                                                                        --Slovakia
                                                                                --Slovenia
                                                                                                                    --Spain
                                                                                --Sweden
                                                                                --Switzerland
                                                                                                                                                                                                                                                                                                                                                                                                                    --United Kingdom
                                                                                                                                                                                                                                                                                                                                                                                --Serbia
                                                                                Middle East
                                                                                                                                                                                                                            --Israel
                                                                                                                                                                                                                                                                                                        --Azerbaijan
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            --Georgia
                                                                                                                                                                                                                                                                                                                                                                                                                    --Kazakhstan
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        --Saudi Arabia
                                                                                                                                                                                                                                                                                                                                                                                                                                                        --Turkey
                                                                                --United Arab Emirates
                                                                                                                    --Uzbekistan
                                                                                                                                                                                                                                                                                                                                                                                                                                                        --Iran
                                                                                                                    North America
                                                                            --United States
                                                                                --Canada
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            --Costa Rica
                                                                                                                                                                                            --Dominican Republic
                                                                                                                                                                                                                                                                                                                                            --Guatemala
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        --Mexico
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        South America
                                                                                                                                                                                                                                                                                                                                                                            --Argentina
                                                                                                                                                                                                                                --Bolivia
                                                                                                                    --Brazil
                                                                                                                                                        --Chile
                                                                                                                    --Colombia
                                                                                                                                                                                                                                                                    --Ecuador
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                --Peru
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    --Uruguay
                                                                                                                    --Venezuela
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

Therapy


All Publishers 9Dimen Research
                        Allied Market Research
                        AMID
                        Beijing Zeefer Consulting
                        CBR Pharma Insights
                        Chlue Research
                        CurrentPartnering
                        Daedal Research
                        data information intelligence GmbH
                        DataGroup Booksellers
                        Euromonitor International
                        Feedback Consulting
                        FirstWord
                        GBI Research
                        GCC
                        Global Industry Analysts
                        Global Markets Direct
                        GlobalData
                        GlobalInfoResearch
                        GMR Data Ltd.
                        Grand View Research, Inc.
                        HeyReport
                        HJResearch
                        ICON Group International
                        iData Research
                        iGATE Research Pvt. Ltd.
                        Infiniti Research
                        Kalorama Information
                        Koncept Analytics
                        Kuick Research
                        La Merie Publishing
                        Life Science Analytics
                        LP Information
                        MarketsandMarkets
                        MicroMarketMonitor
                        MP Advisors
                        Occams Business Research & Consulting
                        Orion Market Research Private Limited
                        P&S Market Research
                        PharmaVision
                        Plimsoll Publishing
                        PNS Pharma
                        Prof Research 
                        Progressive Markets (owned by Antviews Global)
                        QYResearch
                        RCubes Research and Consulting
                        Red Mountain Insights
                        Renub Research
                        Research Facts
                        RNCOS E-Services
                        Rockville Research
                        Select Biosciences Ltd.
                        Stanley Consulting Corporation
                        Stratistics Market Research Consulting
                        The Assessment Group
                        Tuoda Research
                        Visiongain
                    



                            Found
                                 2118 publications                    



Radiotherapy Market by Type (External Beam Radiation Therapy, Internal Radiation Therapy/Brachytherapy, and Systemic Radiation Therapy), and End User (Hospitals & Clinics and Ambulatory...
US$ 5,370.00
 ...  for radiotherapy. Key Players are profiled and their strategies are analyzed thoroughly to understand competitive outlook of the global market. KEY MARKET SEGMENTS BY TYPE External Beam Radiation Therapy By Product Compact Advanced Radiotherapy Systems Cyberknife Gamma Knife Tomotherapy Proton Therapy Systems Conventional Radiotherapy ...  Jun, 2017 140 pages


Intravenous (IV) Therapy and Vein Access Market by Product Type (Implantable Port [Single Lumen Implantable Port and Double Lumen Implantable Port], Intravenous Catheter [Peripheral...
US$ 5,370.00
Intravenous (IV) therapy is the process of infusion of liquid substances, such as electrolytes, medicines, nutrition, and blood-based products, directly into the vein as a therapeutic treatment. Intravenous therapy ...  STKEHOLDERS The study provides an in-depth analysis of the global intravenous therapy and vein access market, with current trends and future estimations to elucidate ...  Jun, 2017 175 pages


Global Cystic Fibrosis Therapeutics Market Outlook 2022
US$ 3,000.00
 ...  by RNCOS titled, "Global Cystic Fibrosis Therapeutics Market Outlook 2022”, unfolds the market dynamics of the cystic fibrosis therapeutics market. According to this new research report, the market for cystic fibrosis therapeutics was valued at US$ 1.94 Billion ...  for largest share in the total cystic fibrosis therapeutics market in 2016. Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major ...  Jul, 2017 140 pages


Physical & Occupational Therapists Revenues Global Report
US$ 950.00
 ...  Coupon value of $300. PHYSICAL & OCCUPATIONAL THERAPISTS REVENUES WORLD REPORT DATABASE EDITION The Market for Physical & Occupational Therapists Revenues in each country by Products & Services. The Physical & Occupational Therapists Revenues World Report covers ...  Jul, 2017 839 pages


Physical & Occupational Therapists Purchasing World Report
US$ 950.00
PHYSICAL & OCCUPATIONAL THERAPISTS PURCHASING WORLD PDF REPORT See descriptive brochure: here The Physical & Occupational Therapists Purchasing World Report gives data on a list of 42 categories of Raw Materials, Semi- ... , by each country, by Year. This Physical & Occupational Therapists Purchasing World Report is a PDF Summary Edition.807 pages. Updated monthly. UPGRADE: A Purchasing World Database Edition of this ...  Jul, 2017 807 pages


Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse
US$ 4,995.00
Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse SUMMARY The pain therapeutics market ...  Jun, 2017 147 pages


Global Stem Cell Therapy Market: Size, Trend, Share, Opportunity Analysis & Forecast, 2014–2025
US$ 3,619.00
 ... , global stem cell therapy market is expected to grow at a CAGR of 12.2% from 2017 to 2025. According to therapy mode, the market is divided into autologous stem cell therapy and allogeneic stem cell therapy. According to application, the market is divided ...  of stem cell therapy. Restraints: Lack of infrastructure needed for the R&D of stem cell therapy. Ethical issues associated with the embryonic stem cells. MARKET PLAYERS: The top players in the global stem cell therapy market include ...  Mar, 2017


Global Plasma Therapy Market: Size, Trend, Share, Opportunity Analysis & Forecast, 2014–2025
US$ 3,619.00
 ...  to sports medicine and orthopedic treatments. Global plasma therapy market is expected to grow at a CAGR of 13.5% from 2017 to 2025. Based on type, the global plasma therapy market is segmented as Leucocyte-rich PRP ...  of platelet rich plasma for treatment of various diseases. Restraints: High cost of plasma therapy. MARKET PLAYERS: The top players in the global plasma therapy market include Biolife Plasma Services, Biotest ...  Mar, 2017


Usher Syndrome - Pipeline Review, H1 2017
US$ 2,000.00
 ... pipeline guide Usher Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development ...  Jun, 2017 34 pages


Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017
US$ 2,000.00
 ... pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development ...  Jun, 2017 73 pages


Hyperinsulinemia - Pipeline Review, H1 2017
US$ 2,000.00
 ... pipeline guide Hyperinsulinemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development ...  Jun, 2017 43 pages


Graves Diseases - Pipeline Review, H1 2017
US$ 2,000.00
 ... pipeline guide Graves Diseases - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development ...  Jun, 2017 30 pages


Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) - Pipeline Review, H1 2017
US$ 3,500.00
 ... Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development ...  Jun, 2017 60 pages


Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H1 2017
US$ 3,500.00
 ... therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development ...  Jun, 2017 44 pages


Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H1 2017
US$ 3,500.00
 ... therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development ...  Jun, 2017 54 pages


Dystrophin (DMD) - Pipeline Review, H1 2017
US$ 3,500.00
Dystrophin (DMD) - Pipeline Review, H1 2017 SUMMARY According to the recently published report 'Dystrophin (DMD) - Pipeline Review, H1 2017'; Dystrophin (DMD) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed ...  Jun, 2017 70 pages


2017 Global and Regional Therapeutic Stent Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors,  ...  etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...  Jun, 2017 145 pages


2017 Global and Regional Therapeutic Nuclear Medicines Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors,  ...  etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...  Jun, 2017 143 pages


2017 Global and Regional Ozone Therapy Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors,  ...  etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...  Jun, 2017 165 pages


2017 Global and Regional Ozone Therapy Instrument Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors,  ...  etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...  Jun, 2017 164 pages


2017 Global and Regional Gene Therapy Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors,  ...  etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...  Jun, 2017 146 pages


2017 Global and Regional Behavioral Therapy Market Research Report Forecasts 2022
US$ 2,800.00
This report focus on Global and regional market, providing information on major players like manufacturers, suppliers, distributors,  ...  etc., major types, major applications from Global and major regions such as Europe, North American, South American, Asia (Excluding China ...  Jun, 2017 189 pages


Global Acne Treatment Market: (2017-2021 Edition)
US$ 700.00
 ...  Report The report entitled “Global Acne Treatment Market: (2017-2021 Edition)”, provides analysis of the global acne treatment market and its products, with detailed analysis of market size and growth in terms ... ) Executive Summary The global acne treatment market is growing rapidly over the years and is expected to increase further in the forecasted period (2017-2021). Global acne treatment is supported by a number of growth ...  Jun, 2017 56 pages


Multiple System Atrophy - Pipeline Review, H1 2017
US$ 2,000.00
 ... Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  Jun, 2017 33 pages


Mucopolysaccharidosis III - Pipeline Review, H1 2017
US$ 2,000.00
 ... Mucopolysaccharidosis III (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  Jun, 2017 61 pages


Mucopolysaccharidosis II - Pipeline Review, H1 2017
US$ 2,000.00
 ... Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  Jun, 2017 57 pages


Mucopolysaccharidosis I - Pipeline Review, H1 2017
US$ 2,000.00
 ... Mucopolysaccharidosis I (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  Jun, 2017 73 pages


Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H1 2017
US$ 3,500.00
 ... Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development ...  Jun, 2017 42 pages


Global Lupus Therapeutic Market 2017-2021
US$ 3,500.00 US$ 2,500.00
 ...  market. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Lupus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and ...  Jun, 2017 82 pages


Global Autologous Cell Therapy Market 2017-2021
US$ 3,500.00 US$ 2,500.00
 ...  of the global autologous cell therapy market for 2017-2021. To calculate the market size, the report considers the sales of autologous stem cell as well non-stem cell products. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Autologous Cell Therapy Market ...  Jun, 2017 92 pages


Epilepsy Therapeutic Market in APAC 2017-2021
US$ 3,500.00 US$ 2,500.00
 ...  market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Epilepsy Therapeutic Market in APAC 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape ...  Jun, 2017 81 pages


Global Bronchitis Spirovital Therapy Units Industry Market Research 2017
US$ 2,600.00
 ...  driving the global Bronchitis Spirovital Therapy Units industry? 8. What are the key market trends impacting the growth of the Bronchitis Spirovital Therapy Units market? 9. What are the Bronchitis Spirovital Therapy Units market challenges to market growth? 10. What are the Bronchitis Spirovital Therapy Units market opportunities and threats faced by the vendors in the global Bronchitis Spirovital Therapy Units market ...  Jun, 2017 165 pages


2017-2022 United States Negative Pressure Wound Therapy Market Report (Status and Outlook)
US$ 3,360.00
 ...  in 48 hours after order is placed. The Negative Pressure Wound Therapy market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top ...  May, 2017 112 pages


2017 Top 5 Negative Pressure Wound Therapy Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
US$ 4,960.00
 ...  Annual Growth Rate) XX% from 2016 to 2022. This report studies Negative Pressure Wound Therapy in Global market, especially in North America, Europe, Asia ... , revenue, market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada and Mexico ... , this report focuses on sales, market share and growth rate of Negative Pressure Wound Therapy in each application, can be divided into Hospital Clinics ...  May, 2017 162 pages


2017-2022 Philippines Negative Pressure Wound Therapy Market Report (Status and Outlook)
US$ 3,360.00
 ...  is sent in 48 hours after order is placed. The Negative Pressure Wound Therapy market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Philippines market, the top ...  May, 2017 112 pages


2017-2022 Malaysia Negative Pressure Wound Therapy Market Report (Status and Outlook)
US$ 3,360.00
 ...  is sent in 48 hours after order is placed. The Negative Pressure Wound Therapy market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with ...  This report focuses on sales, market share and growth rate of Negative Pressure Wound Therapy in each application, split by applications/end use industries, covers ...  May, 2017 112 pages


2017-2022 Japan Negative Pressure Wound Therapy Market Report (Status and Outlook)
US$ 3,360.00
 ...  is sent in 48 hours after order is placed. The Negative Pressure Wound Therapy market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with ...  This report focuses on sales, market share and growth rate of Negative Pressure Wound Therapy in each application, split by applications/end use industries, covers ...  May, 2017 112 pages


2017-2022 India Negative Pressure Wound Therapy Market Report (Status and Outlook)
US$ 3,360.00
 ...  is sent in 48 hours after order is placed. The Negative Pressure Wound Therapy market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with ...  This report focuses on sales, market share and growth rate of Negative Pressure Wound Therapy in each application, split by applications/end use industries, covers ...  May, 2017 112 pages


2017-2022 Global Top Countries Negative Pressure Wound Therapy Market Report
US$ 4,960.00
 ... (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Negative  ... by Countries, this report splits Global into several key Countries, with sales, revenue, market share of top 5 players in these Countries, from 2012 to 2017 (forecast ...  May, 2017 162 pages


2017-2022 China Negative Pressure Wound Therapy Market Report (Status and Outlook)
US$ 3,360.00
 ...  is sent in 48 hours after order is placed. The Negative Pressure Wound Therapy market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with ...  This report focuses on sales, market share and growth rate of Negative Pressure Wound Therapy in each application, split by applications/end use industries, covers ...  May, 2017 112 pages


Adrenoleukodystrophy - Pipeline Review, H1 2017
US$ 2,000.00
 ... Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  May, 2017 61 pages


Global Peptide Therapeutics Market & Clinical Trials Insight 2022
US$ 3,000.00
 ... Therapeutics Peptide Therapeutics by Applications & Indications Peptides Clinical Trials Insight by Phase, Indication & Company Insight on 688 Peptide Drugs in Clinical Trials Clinical & Patent Insight on 119 Marketed Peptides Future Peptide Therapeutics Market Outlook “Global Peptide Therapeutics Market ...  May, 2017 1300 pages


Global Physiotherapy Market 2017-2021
US$ 3,500.00 US$ 2,500.00
 ...  market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Physiotherapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and ...  May, 2017 70 pages


Global Ozone Therapy Instrument Market Research Report 2017
US$ 2,850.00
 ... Ozone Therapy Instrument Market; 3.) the North American Ozone Therapy Instrument Market; 4.) the European Ozone Therapy Instrument Market; 5.) market ...  Apr, 2017 163 pages


Global Ozone Theraphy Market Research Report 2017
US$ 2,850.00
Ozone Theraphy Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market ...  the Asia Ozone Theraphy Market; 3.) the North American Ozone Theraphy Market; 4.) the European Ozone Theraphy Market; 5.) market entry and ...  Apr, 2017 163 pages


Clostridium difficile Infections - Pipeline Review, H1 2017
US$ 2,000.00
 ... Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  May, 2017 188 pages


Chagas Disease - Pipeline Review, H1 2017
US$ 2,000.00
 ... Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  May, 2017 83 pages


Basal Cell Carcinoma - Pipeline Review, H1 2017
US$ 2,000.00
 ... Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  May, 2017 121 pages


Adrenocortical Carcinoma - Pipeline Review, H1 2017
US$ 2,000.00
 ... Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development ...  May, 2017 63 pages


United Kingdom Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022
US$ 1,050.00
 ...  service two new national proton therapy centers in the UK. iGATE RESEARCH report titled “United Kingdom Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022” provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. This ...  May, 2017 49 pages




1
2
3
4
5
>

Skip to top





Market Reports


All Categories  Biotechnology Biomarkers Biomaterials Biosimilars Stem Cell  Diagnostics & Diseases In Vitro Diagnostics Incontinence Cancer Cardiovascular Diabetes Hepatitis  Healthcare Healthcare Services Company Reports Ear Care Eye Care Hospital Medicated Skin Care Therapy Wound Care  Medical Devices Anesthesia & Respiratory Cardiovascular Devices Dental Devices Diabetes Care Diagnostic Equipment Drug Delivery Endoscopy Ear, Nose & Throat (ENT) Devices Healthcare Equipment/Supplies Company Reports Neurology Orthopedic Devices Ophthalmic Surgical Equipment Wound Closure Other Medical Devices  Medical Products Pharmaceuticals Clinical Trials Drug Stores Drugs Pharmaceuticals Company Reports Vaccines  Veterinary 






Need Help?

								+44 20 8123 2220 (UK)
				+1 732 587 5005 (USA)
info@marketpublishers.com







Sales and support:
                    +44 20 8123 2220
            +1 732 587 5005
info@marketpublishers.com
  © 2006-2016 MarketPublishers.com


About Us
Our Clients
Our Publishers
Customer FAQ


Market Reports
New Publications
Reports by Regions
Press-Releases


Terms & Conditions
Privacy Policy
Return Policy
Affiliate Program


Join as Publisher

Follow Us:





















